1002360-09-9

Basic information

• Product Name: (S)-1-Boc-3-(Cbz-amino)-piperidine
• Synonyms: (S)-1-Boc-3-(Cbz-amino)-piperidine ;(S)-1-N-BOC-3-N-(CBZ-AMINO)PIPERIDINE;(S)-3-BENZYLOXYCARBONYLAMINO-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(3S)-3-[[(Phenylmethoxy)carbonyl]amino]-1-piperidinecarboxylic acid tert-butyl ester;(S)-tert-Butyl 3-(((benzyloxy)carbonyl)aMino)piperidine-1-carboxylate;tert-butyl (3S)-3-(benzyloxycarbonylamino)piperidine-1-carboxylate;-tert-Butyl 3-(((benzyloxy)
• CAS NO: 1002360-09-9
• Molecular Formula: C18H26N2O4
• Molecular Weight: 334.41004
• Mol File: 1002360-09-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 471.6 °C at 760 mmHg
• Flash Point: 239 °C
• Appearance: /
• Density: 1.15
• Storage Temp.: 2-8°C
• PKA: 12.05±0.20(Predicted)
• CAS DataBase Reference: (S)-1-Boc-3-(Cbz-amino)-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-Boc-3-(Cbz-amino)-piperidine(1002360-09-9)
• EPA Substance Registry System: (S)-1-Boc-3-(Cbz-amino)-piperidine(1002360-09-9)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 1002360-09-9(Hazardous Substances Data)

Usage

General Description

(S)-1-Boc-3-(Cbz-amino)-piperidine is a chemical compound that is commonly used in the synthesis and production of pharmaceuticals. It is a complex organic molecule with the formula C16H26N2O3, and it contains both a Boc (tert-butoxycarbonyl) and a Cbz (carboxybenzyl) protecting group. (S)-1-Boc-3-(Cbz-amino)-piperidine is important in organic chemistry for the creation of various drugs, as well as in the study of chemical reactions and mechanisms. It is known for its ability to react readily with other compounds, making it a valuable tool in the creation of new pharmaceuticals. Additionally, it is used in the development of new synthetic routes and as a building block for the preparation of biologically active compounds.

Upstream product

• 4129-17-3 diphenylphosphoranyl azide 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 501-53-1 benzyl chloroformate 
• 144243-24-3 tert‐butyl 3‐aminopiperidine‐1‐carboxylate 
• 188111-79-7 tert-butyl (3R)3-aminopiperidine-1-carboxylate 
• 625471-18-3 tert-butyl (3S)-3-aminopiperidine-1-carboxylate 

Downstream Products

• 129888-62-6 N-(1-tert-butoxycarbonyl-3-piperidyl)acetamide 

Relevant articles and documents

Discovery of a novel bicyclic compound, DS54360155, as an orally potent analgesic without mu-opioid receptor agonist activity

We synthesized derivatives of a natural alkaloid, conolidine, and evaluated these derivatives in the acetic acid-induced writhing test and formalin test in ddY mice after oral administration. As a result, we identified (5S)-6-methyl-1,3,4,5,6,8-hexahydro-7H-2,5-methano[1,5]diazonino[7,8-b]indol-7-one sulfate salt, 15a (DS54360155), with a unique and original bicyclic skeleton, as an analgesic more potent than conolidine. Moreover, 15a did not exhibit mu-opioid receptor agonist activity.

Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in?vivo anti-tumor activity

Novel 1H-benzo[d]immidazole-4-carboxamide derivatives bearing five-membered or six-membered N-heterocyclic moieties at the 2-position were designed and synthesized as PARP-1 inhibitors. Structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values in the single or double digit nanomolar level. Some potent PARP-1 inhibitors also had similar inhibitory activities against PARP-2. Among all the synthesized compounds, compound 10a and 11e displayed strong potentiation effects on temozolomide (TMZ) in MX-1?cells (PF50?=?7.10, PF50?=?4.17). In?vivo tumor growth inhibition was investigated using compound 10a in combination with TMZ, and it was demonstrated that compound 10a could strongly potentiate the cytotoxicity of TMZ in MX-1 xenograft tumor model. Two co-crystal structures of compounds 11b and 15e complexed with PARP-1 were achieved and demonstrated a unique binding mode of these benzo-imidazole derivatives.

Indazole-carboxamide compounds

The invention provides novel indazole-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.